Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data

 

• The late clinical-stage cell therapy company, AlloVir, Inc. (NASDAQ:ALVR) announced pre-clinical results for ALVR109, an Off-the-Shelf SARS-CoV-2 Specific T Cell Therapy.
• The data presented at the 62nd American Society of Hematology ASH Annual Meeting over the weekend indicated selective antiviral activity of the experimental therapy against SARS-CoV-2, the virus causing COVID-19.
• A proof-of-concept clinical trial is in progress at the Houston Methodist Hospital to assess the safety and efficacy of ALVR109 in preventing severe disease in hospitalized COVID-19 patients with high-risk features.
• The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses in patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases.
• “It’s increasingly clear that T cell dysregulation is a critical factor in the development of severe COVID-19 and that the presence of healthy SARS-CoV-2-specific CD4+ and CD8+ T cells is important in helping patients fight off the virus,” said Ann Leen, Ph.D., Chief Scientific Officer at AlloVir.
• https://seekingalpha.com/news/3642095-allovirs-covidminus-19-therapy-saw-anti-viral-activity-in-pre-clinical-data